Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07145229 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

A Phase 2 study of Gout Flare and Acute Gouty Arthritis, sponsored by Atom Therapeutics Co..

Recruiting
Registry status
Phase 2
Development phase
380
Enrollment target
20
Study locations

NCT07145229: Recruiting Phase 2 study of Gout Flare and Acute Gouty Arthritis, sponsored by Atom Therapeutics Co..

NCT07145229 is a Phase 2 study of Gout Flare and Acute Gouty Arthritis that is actively recruiting participants, run by Atom Therapeutics Co.. The registered enrollment target is 380 participants, below the 726-participant average among 5 other Gout Flare trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07145229, a Phase 2 study of Gout Flare and Acute Gouty Arthritis, is actively recruiting participants, sponsored by Atom Therapeutics Co..

RECRUITING
Registry status
Phase 2
Development phase
380 participants
Enrollment target
20
Study locations

Study Summary

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Primary Outcome

Change from baseline in 0-100 mm VAS pain score of the target joint

Conditions Studied

Gout Flare Acute Gouty Arthritis Acute Gout Flare Gout Flares

Interventions

  • DRUG Placebo
  • DRUG Colchicine
  • DRUG ABP-745 Dose A
  • DRUG ABP-745 Dose B

Study Locations (20)

New South Wales

  • Emeritus Sydney - Botany
  • Canopy Clinical Research Northern Beaches - Brookvale
  • Novatrials - Kotara
  • Genesis Research Services - Newcastle

Louisiana

  • Northshore Research Associates - Alexandria
  • DelRicht Research - Baton Rouge
  • DelRicht Research - New Orleans

Victoria

  • Emeritus Melbourne - Camberwell
  • Canopy Clinical Research Altona North - North Altona

Arizona

  • Onyx Clinical Research - Peoria

California

  • Exinia Research - La Mesa

Georgia

  • Evergreen Clinical Trial - Norcross

Illinois

  • Bioluminux Clinical Research - Naperville

Iowa

  • Exinia Research - Des Moines

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2025-08-26
Est. Completion 2026-06
Phase Phase 2
Atom Therapeutics Co.

9 total trials

What NCT07145229 shows while recruiting

NCT07145229 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 726-participant average among 5 other Gout Flare trials with a reported enrollment target (48% lower).

The record links to 4 conditions, with Gout Flare appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT07145229 names 20 study sites across 14 states, led by New South Wales, Louisiana, Victoria.

Frequently Asked Questions

What is clinical trial NCT07145229 about?

NCT07145229 is a clinical study titled "Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare". A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in pa...

What is the current status of trial NCT07145229?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2025-08-26. Estimated completion is 2026-06.

What conditions does trial NCT07145229 study?

This clinical trial studies the following conditions: Gout Flare, Acute Gouty Arthritis, Acute Gout Flare, Gout Flares.

What interventions are being tested in trial NCT07145229?

The interventions under investigation include: Placebo (DRUG), Colchicine (DRUG), ABP-745 Dose A (DRUG), ABP-745 Dose B (DRUG).

Who is sponsoring clinical trial NCT07145229?

This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07145229 being conducted?

This trial has 20 study locations across Arizona, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gout Flare

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04560673 · 380 participants · Phase 2

    Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

  • NCT04777357 · 380 participants · Phase 3

    A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

  • NCT04821154 · 380 participants

    Persona Revision Knee System Outcomes

  • NCT05102019 · 380 participants · NA

    Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07145229

Source: ClinicalTrials.gov NCT07145229, the US trial registry maintained by the National Library of Medicine. NCT07145229 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.